- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- [ 18F]F-AraG PET
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Stanford, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 241–264
of 3,814
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Aggressive Non-Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Hepatosplenic T-Cell Lymphoma, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Mediastinal (Thymic) Large B-Cell Lymphoma, Nasal Type Extranodal NK/T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Primary Cutaneous Anaplastic Large Cell Lymphoma, Refractory Anaplastic Large Cell Lymphoma, Small Lymphocytic Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma
- Interventions
- Cholecalciferol, Laboratory Biomarker Analysis
- Dietary Supplement · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 565 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2028
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • Atlanta, Georgia • Iowa City, Iowa + 2 more
- Conditions
- Mild or Moderate Surgical Bleeding
- Interventions
- Fibrocaps, Gelatin sponge
- Biological
- Lead sponsor
- Mallinckrodt
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 721 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orange, California + 24 more
- Conditions
- Alzheimer Disease, Early Onset, Alzheimer Disease, Alzheimer Dementia, Mild Cognitive Impairment, Memory Disorders, Memory Loss, Memory Impairment, Memory Disorders, Age Related, Alzheimer Disease, Late Onset, Cognitive Impairment, Dementia, Mild, Dementia, Alzheimer Type, Cognitive Decline
- Interventions
- GammaSense Stimulation System (non-invasive, non-significant risk)
- Device
- Lead sponsor
- Cognito Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Newton, Massachusetts
- Conditions
- Non-Hodgkin's Lymphoma, Plasma Cell Myeloma
- Interventions
- Hematopoietic Cell Transplantation, Tbo-filgrastim, Laboratory Biomarker Analysis
- Procedure · Drug · Other
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Diffuse Large B Cell Lymphoma
- Interventions
- 18F-FluorApoTrace
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma
- Interventions
- aldesleukin, filgrastim, cyclophosphamide, etoposide, radiation therapy, peripheral blood stem cell transplantation, bone marrow ablation with stem cell support
- Biological · Drug · Radiation + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 16 Years to 60 Years
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1995
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Lymphoma, Mantle Cell, Mantle Cell Lymphoma
- Interventions
- Rituximab (R), EPOCH, Bortezomib (B), Bortezomib, Bortezomib or observation
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2022
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Chronic Lymphoid Leukemia, Lymphoid Malignancies, Non-Hodgkin's Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Peripheral T-cell Lymphoma
- Interventions
- ABT-263
- Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2016
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Bethesda, Maryland • Boston, Massachusetts + 3 more
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Interventions
- rabbit anti-thymocyte globulin (ATG), therapeutic allogeneic lymphocytes, busulfan, fludarabine phosphate, tacrolimus, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, methotrexate
- Biological · Drug · Procedure
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2015
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Non-Hodgkin Lymphoma
- Interventions
- Not listed
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 8
- States / cities
- Miami, Florida • Atlanta, Georgia • Iowa City, Iowa + 5 more
- Conditions
- Lymphoma, Non-Hodgkin
- Interventions
- TAK-981, Rituximab
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Ann Arbor, Michigan • Rochester, Minnesota + 9 more
- Conditions
- Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma
- Interventions
- Bortezomib, Dexamethasone, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Rituximab, Temsirolimus
- Drug · Other · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2021
- U.S. locations
- 11
- States / cities
- Denver, Colorado • Atlanta, Georgia • Rochester, Minnesota + 7 more
- Conditions
- Leukemia
- Interventions
- Cytarabine, Fludarabine, Oxaliplatin, Rituximab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2011
- U.S. locations
- 2
- States / cities
- La Jolla, California • Boston, Massachusetts
- Conditions
- Non-hodgkin Lymphoma
- Interventions
- Venetoclax
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio
- Conditions
- Advanced Solid Tumor, Advanced Lymphoma
- Interventions
- SNX281, pembrolizumab
- Drug
- Lead sponsor
- Stingthera, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 4
- States / cities
- Denver, Colorado • Sarasota, Florida • Philadelphia, Pennsylvania + 1 more
- Conditions
- Lymphoma, Non-Hodgkin, Lymphoma, Low-Grade
- Interventions
- ibritumomab tiuxetan (Zevalin®)
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 8
- States / cities
- Loma Linda, California • Oceanside, California • Fairfield, Connecticut + 5 more
- Conditions
- Diffuse Large B-cell Lymphoma, High-Grade B-cell Lymphoma
- Interventions
- RO6870810, Venetoclax, Rituximab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 4
- States / cities
- Duarte, California • Stanford, California • New York, New York + 1 more
- Conditions
- Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Non-Hodgkin Lymphoma, Chronic Myelogenous Leukemia
- Interventions
- Expansion of umbilical cord stem cells
- Procedure
- Lead sponsor
- ViaCell
- Industry
- Eligibility
- 12 Years to 60 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 4
- States / cities
- Maywood, Illinois • Indianapolis, Indiana • Hackensack, New Jersey + 1 more
- Conditions
- Mycosis Fungoides, Sezary Syndrome, Mycosis Fungoides/Sezary Syndrome
- Interventions
- Tulmimetostat
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Asthma
- Interventions
- NC100182 Hyperpolarized 3He
- Other
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 6 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2021
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Relapsed/Refractory Peripheral T-cell Lymphoma
- Interventions
- Tolinapant, Decitabine + Cedazuridine
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 6
- States / cities
- Aurora, Colorado • Tampa, Florida • Atlanta, Georgia + 3 more
- Conditions
- Kidney Cancer, Leukemia, Lymphoma, Myelodysplastic Syndromes, Neuroblastoma, Sarcoma
- Interventions
- filgrastim, allogeneic bone marrow transplantation
- Biological · Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 18 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 2
- States / cities
- Nashville, Tennessee • Seattle, Washington
- Conditions
- B-Cell Non-Hodgkin Lymphoma-Recurrent, Diffuse Large B-Cell Lymphoma-Recurrent, Follicular Lymphoma-Recurrent, High Grade B-Cell Lymphoma-Recurrent, Primary Mediastinal Large B-Cell Lymphoma-Recurrent, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent, B-Cell Non-Hodgkin Lymphoma-Refractory, Diffuse Large B-Cell Lymphoma-Refractory, Follicular Lymphoma-Refractory, High Grade B-Cell Lymphoma-Refractory, Primary Mediastinal Large B-Cell Lymphoma-Refractory, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Refractory
- Interventions
- Biopsy, Biospecimen Collection, Computed Tomography, Golcadomide, Positron Emission Tomography, Rituximab
- Procedure · Drug · Biological
- Lead sponsor
- Nathan Denlinger
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio